Laddar populära aktier...
Sprint Bioscience delivered Q3 sales within the recent range at SEK 14.
Sprint Bioscience has Q2 sales of SEK 16.7m (17.9m in Q1 and SEK 0m in Q2 2023), and the cash balance was SEK 36m (39.
Recorded sales improved to SEK 16.7m (17.9m in Q1 and SEK 0m in Q2 2023), and the cash balance was SEK 36m (39.
Sprint Bioscience recorded sales improved to SEK 17.
Recorded sales improved to SEK 17.9m (10.9m in Q4 and SEK 0m in Q1 2023), and the cash balance was SEK 39.
The internal DISA program is based on the TREX1 inhibition pathway, which potentially supports the effect of immuno-oncology therapy, radiat...
Sprint Bioscience recorded sales improved to SEK 10.
Redeye provides a brief comment on Sprint Bioscience’s Q4 report.
Sprint Bioscience is looking to replace Decipher as a partner for VPS34 as soon as the project is handed back.
Sprint Bioscience (Sprint) meddelar att Deciphera har valt att returnera VPS34-hämmarprogrammet utan att ge något specifikt förtydligande.
Redeye reviews the Sprint Bioscience case following a change of analyst and provide a more in-depth take on the company’s recent VADA deal.
Redeye provides a brief comment on Sprint Bioscience’s Q3 report.
Redeye provides a brief comment on Sprint Bioscience’s Q2 report.
Redeye endorses yesterday's news that Sprint Bioscience has licensed the global rights to its cancer program VADA (VRK1) to Day One Biopharm...
Redeye adjusts its estimates for the return of NASH to Sprint Bioscience.
Redeye is disappointed to learn that Sprint Bioscience will receive back the NASH program from LG Chem.
Redeye provides its comment on Sprint Bioscience’s Q1 2023 report, and we judge that the company needs to close a VADA deal in the near futu...
Redeye comments on Sprint Bioscience’s Q4 2022 report, and we judge that the company is closing in on a licensing deal for its VADA project ...
In this episode, we are joined by Jessica Martinsson, COO of Sprint Bioscience, alongside European patent attorneys Joanna Applequist and Mi...
Redeye is disappointed to learn that Sprint’s former partner, Hibercell, returned the PETRA01 project to Sprint.
Redeye comments on Sprint Bioscience’s Q3 2022 report, and we judge that the company is closing in on a licensing deal for its VADA project ...
Redeye comments on Sprint Bioscience announcing a rights issue.
Redeye comments on Sprint’s Q2 2022 report, which aligned with our expectations.
Redeye comments on Sprint’s Q1 2022 report, with the company recently announcing the target and launch date for its internal NIMA project.
Redeye comments on Sprint’s Q4 2021 report, representing a relatively calm quarter on the news front.
